Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 10, 2012, Pages 1331-1334

  Althomsons, Sandy P ^a   Cegielski, J P ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Drug resistant TB; Second line resistance; Treatment outcomes

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; SECOND LINE TUBERCULOSTATIC AGENT; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; SECOND LINE DRUG RESISTANT TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS CONTROL; UNITED STATES;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84866465879     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0812     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention Task Force. National Action Plan to combat multidrug-resistant tuberculosis. MMWR Recomm Rep 1992; 41 (RR-11): 1-48.
2. Pratt R, Price S, Miramontes R, Navin T. Trends in tuberculosis-United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60: 333-337.
3. Wright A, Bai G, Barrera L, et al. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs - worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-305.
4. Iseman M. A clinician's guide to tuberculosis. Philadelphia, PA, USA: Lippincott, Williams and Wilkins, 2000.
5. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2009. Atlanta, GA, USA: US Department of Health and Human Services, CDC, 2010.
6. Curtis A B, McCray E, McKenna M, Onorator I M. Completeness and timeliness of tuberculosis case reporting: a multistate study. Am J Prev Med 2001; 20: 108-112. (Pubitemid 32109228)
7. Sprinson J E, Lawton E S, Porco T C, Flood J M, Westenhouse J L. Assessing the validity of tuberculosis surveillance data in California. BMC Public Health 2006; 6: 217.
8. Yokoe D S, Coon S W, Dokholyan R, et al. Pharmacy data for tuberculosis surveillance and assessment of patient management. Emerging Infect Dis 2004; 10: 1426-1431. (Pubitemid 39014156)
9. Armitage P, Berry G. Statistical methods in medical research. Oxford, UK: Blackwell Scientific Publications, 1994.
10. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep 1998; 47 (RR-20): 1-51.
11. National Committee for Clinical Laboratory Standards. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes; approved standard. NCCLS Document M24-A. Wayne, PA, USA: NCCLS, 2003.
12. LoBue P, Sizemore C, Castro K G. Plan to combat extensively drug-resistant tuberculosis. Recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep 2009; 58 (RR-03): 1-43.